Korro Bio (KRRO) filed a registration statement Monday with the US Securities and Exchange Commission covering the potential sale of up to $400 million of its securities from time to time.
The filing covers a base prospectus for up to $400 million of debt securities, common stock, preferred stock, units, and warrants in one or more offerings, including an "at the market offering" of up to $100 million of common shares under a sales agreement with TD Securities.
Proceeds will be used for general corporate purposes.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。